



## PhenoSeek AML Flow Cytometry Panel

Acute Myeloid Leukemia (AML) is a type of cancer in which the bone marrow makes abnormal leukemic cells which spread from the bone marrow to the blood and other parts of the body. The road to an effective treatment for AML patients has been challenging due to the heterogeneity of the disease. As experts in hematological malignancies, Champions Oncology has developed and optimized the PhenoSeek AML Flow Cytometry Panel in order to interrogate multiple AML populations as well as other immune cell subsets within each clinical sample. This 18-color panel includes comprehensive immunophenotyping markers for immune cell populations as well as leukemic cell markers detecting AML subset populations. The PhenoSeek AML flow cytometry panel also includes a Live/Dead staining component, which allows for clean separation of the diverse subsets without risking dead cell contamination. Because Champions Oncology has the capacity to execute up to 28-color fully optimized and validated GCLP flow cytometry panels in one tube, therefore maximizing the value of your clinical trial samples, this panel leaves open channels to allow you to customize this panel to meet your exploratory clinical trial requirements.




## PhenoSeek AML – Gating Strategy

Whole Blood was collected in EDTA tubes and delivered overnight to Champions Oncology for assessment. Red blood cells were lysed, samples were washed and stained with panel specific fluorescent antibodies and a live/dead staining component. Samples were collected on Champions' BD Symphony instrument and analysis was completed using FlowJo Software.




### AML Subset Populations: Short Term Stability

Evaluation of short term stability was completed using 3 AML Models from Champions' hematological tumor bank. All 5 AML subset population markers remained stable at 72hrs in the assessment.



### AML Subset Populations: Lower Limit of Detection (LLOD)

The LLOD for 5 AML subset populations was determined using 3 AML Models from Champions' hematological tumor bank. All AML subset populations can be confidently detected with as little as 400 AML cells in a total of 500,000 cells.



©: CV>35%

*Our scientific experts in clinical flow cytometry can provide advice and guidance for all of your upcoming clinical trial needs. Learn more about adding the PhenoSeek AML flow cytometry panel to your next trial.*